N@N

Andrew Fein Maintained (UTHR) at Strong Buy with Increased Target to $400 on, Jul 25th, 2024

^{Published on 2024-10-28 12:44:50 - WOPRAI, Andrew Fein}
 

Andrew Fein of HC Wainwright & Co., Maintained "United Therapeutics Corporation" (UTHR) at Strong Buy with Increased Target from $300 to $400 on, Jul 25th, 2024.

Andrew has made no other calls on UTHR in the last 4 months.

There are 7 other peers that have a rating on UTHR. Out of the 7 peers that are also analyzing UTHR, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Terence Flynn of "Morgan Stanley" Downgraded from Buy to Hold and Increased Target to $321 on, Thursday, July 11th, 2024
• Chris Shibutani of "Goldman Sachs" Maintained at Hold with Increased Target to $240 on, Friday, May 3rd, 2024

These are the ratings of the 5 analyists that currently disagree with Andrew

---

• Joseph Thome of "TD Cowen" Maintained at Strong Buy with Increased Target to $350 on, Thursday, July 11th, 2024
• Ashwani Verma of "UBS" Maintained at Strong Buy with Increased Target to $370 on, Monday, July 8th, 2024
• Tiago Fauth of "Wells Fargo" Maintained at Buy with Increased Target to $350 on, Wednesday, June 12th, 2024
• Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $300 on, Tuesday, May 21st, 2024
• Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $400 on, Thursday, May 2nd, 2024

Contributing Sources

---